Enalapril in infants with single ventricle: Results of a multicenter randomized trial

Daphne T. Hsu, Victor Zak, Lynn Mahony, Lynn A. Sleeper, Andrew M. Atz, Jami C. Levine, Piers C. Barker, Chitra Ravishankar, Brian W. McCrindle, Richard V. Williams, Karen Altmann, Nancy S. Ghanayem, Renee Margossian, Wendy K. Chung, William L. Border, Gail D. Pearson, Mario P. Stylianou, Seema Mital

Research output: Contribution to journalArticle

167 Citations (Scopus)

Abstract

Background-: Angiotensin-converting enzyme inhibitor therapy improves clinical outcome and ventricular function in adults with heart failure. Infants with single-ventricle physiology have poor growth and are at risk for abnormalities in ventricular systolic and diastolic function. The ability of angiotensin-converting enzyme inhibitor therapy to preserve ventricular function and improve somatic growth and outcomes in these infants is unknown. Methods and results-: The Pediatric Heart Network conducted a double-blind trial involving 230 infants with single-ventricle physiology randomized to receive enalapril (target dose 0.4 mg • kg • d) or placebo who were followed up until 14 months of age. The primary end point was weight-for-age z score at 14 months. The primary analysis was intention to treat. A total of 185 infants completed the study. There were 24 and 21 withdrawals or deaths in the enalapril and placebo groups, respectively (P=0.74). Weight-for-age z score was not different between the enalapril and placebo groups (mean±SE-0. 62±0.13 versus-0.42±0.13, P=0.28). There were no significant group differences in height-for-age z score, Ross heart failure class, brain natriuretic peptide concentration, Bayley scores of infant development, or ventricular ejection fraction. The incidence of death or transplantation was 13% and did not differ between groups. Serious adverse events occurred in 88 patients in the enalapril group and 87 in the placebo group. Conclusions-: Administration of enalapril to infants with single-ventricle physiology in the first year of life did not improve somatic growth, ventricular function, or heart failure severity. The results of this randomized trial do not support the routine use of enalapril in this population.

Original languageEnglish (US)
Pages (from-to)333-340
Number of pages8
JournalCirculation
Volume122
Issue number4
DOIs
StatePublished - Jul 27 2010
Externally publishedYes

Fingerprint

Enalapril
Multicenter Studies
Ventricular Function
Placebos
Enzyme Therapy
Heart Failure
Angiotensin-Converting Enzyme Inhibitors
Growth
Weights and Measures
Intention to Treat Analysis
Aptitude
Brain Natriuretic Peptide
Child Development
Stroke Volume
Transplantation
Pediatrics
Incidence
Population

Keywords

  • angiotensin
  • congenital
  • heart defects
  • heart failure
  • pediatrics
  • trials

ASJC Scopus subject areas

  • Physiology (medical)
  • Cardiology and Cardiovascular Medicine

Cite this

Hsu, D. T., Zak, V., Mahony, L., Sleeper, L. A., Atz, A. M., Levine, J. C., ... Mital, S. (2010). Enalapril in infants with single ventricle: Results of a multicenter randomized trial. Circulation, 122(4), 333-340. https://doi.org/10.1161/CIRCULATIONAHA.109.927988

Enalapril in infants with single ventricle : Results of a multicenter randomized trial. / Hsu, Daphne T.; Zak, Victor; Mahony, Lynn; Sleeper, Lynn A.; Atz, Andrew M.; Levine, Jami C.; Barker, Piers C.; Ravishankar, Chitra; McCrindle, Brian W.; Williams, Richard V.; Altmann, Karen; Ghanayem, Nancy S.; Margossian, Renee; Chung, Wendy K.; Border, William L.; Pearson, Gail D.; Stylianou, Mario P.; Mital, Seema.

In: Circulation, Vol. 122, No. 4, 27.07.2010, p. 333-340.

Research output: Contribution to journalArticle

Hsu, DT, Zak, V, Mahony, L, Sleeper, LA, Atz, AM, Levine, JC, Barker, PC, Ravishankar, C, McCrindle, BW, Williams, RV, Altmann, K, Ghanayem, NS, Margossian, R, Chung, WK, Border, WL, Pearson, GD, Stylianou, MP & Mital, S 2010, 'Enalapril in infants with single ventricle: Results of a multicenter randomized trial', Circulation, vol. 122, no. 4, pp. 333-340. https://doi.org/10.1161/CIRCULATIONAHA.109.927988
Hsu, Daphne T. ; Zak, Victor ; Mahony, Lynn ; Sleeper, Lynn A. ; Atz, Andrew M. ; Levine, Jami C. ; Barker, Piers C. ; Ravishankar, Chitra ; McCrindle, Brian W. ; Williams, Richard V. ; Altmann, Karen ; Ghanayem, Nancy S. ; Margossian, Renee ; Chung, Wendy K. ; Border, William L. ; Pearson, Gail D. ; Stylianou, Mario P. ; Mital, Seema. / Enalapril in infants with single ventricle : Results of a multicenter randomized trial. In: Circulation. 2010 ; Vol. 122, No. 4. pp. 333-340.
@article{9a18741961c64fa097ebed6b99c91fa0,
title = "Enalapril in infants with single ventricle: Results of a multicenter randomized trial",
abstract = "Background-: Angiotensin-converting enzyme inhibitor therapy improves clinical outcome and ventricular function in adults with heart failure. Infants with single-ventricle physiology have poor growth and are at risk for abnormalities in ventricular systolic and diastolic function. The ability of angiotensin-converting enzyme inhibitor therapy to preserve ventricular function and improve somatic growth and outcomes in these infants is unknown. Methods and results-: The Pediatric Heart Network conducted a double-blind trial involving 230 infants with single-ventricle physiology randomized to receive enalapril (target dose 0.4 mg • kg • d) or placebo who were followed up until 14 months of age. The primary end point was weight-for-age z score at 14 months. The primary analysis was intention to treat. A total of 185 infants completed the study. There were 24 and 21 withdrawals or deaths in the enalapril and placebo groups, respectively (P=0.74). Weight-for-age z score was not different between the enalapril and placebo groups (mean±SE-0. 62±0.13 versus-0.42±0.13, P=0.28). There were no significant group differences in height-for-age z score, Ross heart failure class, brain natriuretic peptide concentration, Bayley scores of infant development, or ventricular ejection fraction. The incidence of death or transplantation was 13{\%} and did not differ between groups. Serious adverse events occurred in 88 patients in the enalapril group and 87 in the placebo group. Conclusions-: Administration of enalapril to infants with single-ventricle physiology in the first year of life did not improve somatic growth, ventricular function, or heart failure severity. The results of this randomized trial do not support the routine use of enalapril in this population.",
keywords = "angiotensin, congenital, heart defects, heart failure, pediatrics, trials",
author = "Hsu, {Daphne T.} and Victor Zak and Lynn Mahony and Sleeper, {Lynn A.} and Atz, {Andrew M.} and Levine, {Jami C.} and Barker, {Piers C.} and Chitra Ravishankar and McCrindle, {Brian W.} and Williams, {Richard V.} and Karen Altmann and Ghanayem, {Nancy S.} and Renee Margossian and Chung, {Wendy K.} and Border, {William L.} and Pearson, {Gail D.} and Stylianou, {Mario P.} and Seema Mital",
year = "2010",
month = "7",
day = "27",
doi = "10.1161/CIRCULATIONAHA.109.927988",
language = "English (US)",
volume = "122",
pages = "333--340",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Enalapril in infants with single ventricle

T2 - Results of a multicenter randomized trial

AU - Hsu, Daphne T.

AU - Zak, Victor

AU - Mahony, Lynn

AU - Sleeper, Lynn A.

AU - Atz, Andrew M.

AU - Levine, Jami C.

AU - Barker, Piers C.

AU - Ravishankar, Chitra

AU - McCrindle, Brian W.

AU - Williams, Richard V.

AU - Altmann, Karen

AU - Ghanayem, Nancy S.

AU - Margossian, Renee

AU - Chung, Wendy K.

AU - Border, William L.

AU - Pearson, Gail D.

AU - Stylianou, Mario P.

AU - Mital, Seema

PY - 2010/7/27

Y1 - 2010/7/27

N2 - Background-: Angiotensin-converting enzyme inhibitor therapy improves clinical outcome and ventricular function in adults with heart failure. Infants with single-ventricle physiology have poor growth and are at risk for abnormalities in ventricular systolic and diastolic function. The ability of angiotensin-converting enzyme inhibitor therapy to preserve ventricular function and improve somatic growth and outcomes in these infants is unknown. Methods and results-: The Pediatric Heart Network conducted a double-blind trial involving 230 infants with single-ventricle physiology randomized to receive enalapril (target dose 0.4 mg • kg • d) or placebo who were followed up until 14 months of age. The primary end point was weight-for-age z score at 14 months. The primary analysis was intention to treat. A total of 185 infants completed the study. There were 24 and 21 withdrawals or deaths in the enalapril and placebo groups, respectively (P=0.74). Weight-for-age z score was not different between the enalapril and placebo groups (mean±SE-0. 62±0.13 versus-0.42±0.13, P=0.28). There were no significant group differences in height-for-age z score, Ross heart failure class, brain natriuretic peptide concentration, Bayley scores of infant development, or ventricular ejection fraction. The incidence of death or transplantation was 13% and did not differ between groups. Serious adverse events occurred in 88 patients in the enalapril group and 87 in the placebo group. Conclusions-: Administration of enalapril to infants with single-ventricle physiology in the first year of life did not improve somatic growth, ventricular function, or heart failure severity. The results of this randomized trial do not support the routine use of enalapril in this population.

AB - Background-: Angiotensin-converting enzyme inhibitor therapy improves clinical outcome and ventricular function in adults with heart failure. Infants with single-ventricle physiology have poor growth and are at risk for abnormalities in ventricular systolic and diastolic function. The ability of angiotensin-converting enzyme inhibitor therapy to preserve ventricular function and improve somatic growth and outcomes in these infants is unknown. Methods and results-: The Pediatric Heart Network conducted a double-blind trial involving 230 infants with single-ventricle physiology randomized to receive enalapril (target dose 0.4 mg • kg • d) or placebo who were followed up until 14 months of age. The primary end point was weight-for-age z score at 14 months. The primary analysis was intention to treat. A total of 185 infants completed the study. There were 24 and 21 withdrawals or deaths in the enalapril and placebo groups, respectively (P=0.74). Weight-for-age z score was not different between the enalapril and placebo groups (mean±SE-0. 62±0.13 versus-0.42±0.13, P=0.28). There were no significant group differences in height-for-age z score, Ross heart failure class, brain natriuretic peptide concentration, Bayley scores of infant development, or ventricular ejection fraction. The incidence of death or transplantation was 13% and did not differ between groups. Serious adverse events occurred in 88 patients in the enalapril group and 87 in the placebo group. Conclusions-: Administration of enalapril to infants with single-ventricle physiology in the first year of life did not improve somatic growth, ventricular function, or heart failure severity. The results of this randomized trial do not support the routine use of enalapril in this population.

KW - angiotensin

KW - congenital

KW - heart defects

KW - heart failure

KW - pediatrics

KW - trials

UR - http://www.scopus.com/inward/record.url?scp=77955172447&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955172447&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.109.927988

DO - 10.1161/CIRCULATIONAHA.109.927988

M3 - Article

C2 - 20625111

AN - SCOPUS:77955172447

VL - 122

SP - 333

EP - 340

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 4

ER -